Bank of New York Mellon Corp purchased a new position in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 350,857 shares of the biotechnology company's stock, valued at approximately $5,954,000. Bank of New York Mellon Corp owned 0.27% of Aurinia Pharmaceuticals as of its most recent SEC filing.
Several other institutional investors also recently made changes to their positions in AUPH. BOK Financial Private Wealth Inc. acquired a new stake in shares of Aurinia Pharmaceuticals during the 4th quarter valued at approximately $32,000. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Aurinia Pharmaceuticals during the third quarter valued at approximately $48,000. Frazier Financial Advisors LLC boosted its position in Aurinia Pharmaceuticals by 411.9% during the first quarter. Frazier Financial Advisors LLC now owns 3,471 shares of the biotechnology company's stock worth $51,000 after acquiring an additional 2,793 shares during the last quarter. Kemnay Advisory Services Inc. acquired a new stake in Aurinia Pharmaceuticals during the fourth quarter worth approximately $82,000. Finally, Optiver Holding B.V. grew its stake in Aurinia Pharmaceuticals by 1,008.1% in the 1st quarter. Optiver Holding B.V. now owns 6,815 shares of the biotechnology company's stock worth $101,000 after acquiring an additional 6,200 shares during the period. 36.83% of the stock is currently owned by hedge funds and other institutional investors.
Aurinia Pharmaceuticals Stock Performance
Shares of AUPH stock opened at $16.08 on Friday. The company has a market cap of $2.14 billion, a P/E ratio of 7.02 and a beta of 1.40. Aurinia Pharmaceuticals Inc has a 52 week low of $10.34 and a 52 week high of $19.25. The company has a quick ratio of 4.97, a current ratio of 5.42 and a debt-to-equity ratio of 0.07. The business has a 50 day moving average of $15.81 and a two-hundred day moving average of $15.55.
Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last released its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.24 by $0.04. Aurinia Pharmaceuticals had a return on equity of 26.11% and a net margin of 100.84%.The business had revenue of $58.57 million during the quarter, compared to analyst estimates of $80.45 million. As a group, analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.79 EPS for the current year.
Analyst Upgrades and Downgrades
Several equities analysts recently commented on AUPH shares. Zacks Research lowered Aurinia Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 21st. Wall Street Zen downgraded shares of Aurinia Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 8th. Royal Bank Of Canada increased their price objective on shares of Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the stock a "sector perform" rating in a research report on Friday, August 7th. Weiss Ratings upgraded Aurinia Pharmaceuticals from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, August 26th. Finally, Bloom Burton raised Aurinia Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 20th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $17.67.
Check Out Our Latest Research Report on Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Profile
(
Free Report)
Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company's proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.
The company's lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Aurinia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurinia Pharmaceuticals wasn't on the list.
While Aurinia Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
